

---

**DMPH QIP DIRECTED PAYMENTS (January 1, 2021 – December 31, 2023)**  
**Section 438.6(c) Preprint**

---

Section 438.6(c) provides States with the flexibility to implement delivery system and provider payment initiatives under MCO, PIHP, or PAHP Medicaid managed care contracts. Section 438.6(c)(1) describes types of payment arrangements that States may use to direct expenditures under the managed care contract – paragraph (c)(1)(i) provides that States may specify in the contract that managed care plans adopt value-based purchasing models for provider reimbursement; paragraph (c)(1)(ii) provides that States have the flexibility to require managed care plan participation in broad-ranging delivery system reform or performance improvement initiatives; and paragraph (c)(1)(iii) provides that States may require certain payment levels for MCOs, PIHPs, and PAHPs to support State practices critical to ensuring timely access to high-quality care.

Under section 438.6(c)(2), contract arrangements that direct the MCO's, PIHP's, or PAHP's expenditures under paragraphs (c)(1)(i) through (iii) must have written approval from CMS prior to implementation and before approval of the corresponding managed care contract(s) and rate certification(s). This preprint implements the prior approval process and must be completed, submitted, and approved by CMS before implementing any of the specific payment arrangements described in section 438.6(c)(1)(i) through (iii).

**Standard Questions for All Payment Arrangements**

*In accordance with §438.6(c)(2)(i), the following questions must be completed.*

**DATE AND TIMING INFORMATION:**

1. Identify the State's managed care contract rating period for which this payment arrangement will apply (for example, July 1, 2017 through June 30, 2018):

Calendar Year (CY) 2021: January 1, 2021 through December 31, 2021

CY 2022: January 1, 2022 through December 31, 2022

CY 2023: January 1, 2023 through December 31, 2023

2. Identify the State's requested start date for this payment arrangement (for example, January 1, 2018):

January 1, 2021

3. Identify the State’s expected duration for this payment arrangement (for example, 1 year, 3 years, or 5 years):

3 years; Program Year 4 (PY 4, CY 2021) through PY 6 (CY 2023). The State anticipates submitting subsequent preprints to continue the District and Municipal Public Hospital (DMPH) Quality Incentive Pool (QIP) program. The payment arrangement described in this preprint constitutes the total DMPH QIP program payment for PYs 4-6 and supersedes all other payment authorizations for the DMPH QIP program during that period.

**STATE DIRECTED VALUE-BASED PURCHASING:**

4. In accordance with §438.6(c)(1)(i) and (ii), the State is requiring the MCO, PIHP, or PAHP to implement value-based purchasing models for provider reimbursement, such as alternative payment models (APMs), pay for performance arrangements, bundled payments, or other service payment models intended to recognize value or outcomes over volume of services; or the State is requiring the MCO, PIHP, or PAHP to participate in a multi-payer or Medicaid-specific delivery system reform or performance improvement initiative. *Check all that apply; if none are checked, proceed to Question 6.*

- Quality Payments / Pay for Performance (Category 2 APM, or similar)
- Bundled Payments / Episode-Based Payments (Category 3 APM, or similar)
- Population-Based Payments / Accountable Care Organization (ACO) (Category 4 APM, or similar)
- Multi-Payer Delivery System Reform
- Medicaid-Specific Delivery System Reform
- Performance Improvement Initiative
- Other Value-Based Purchasing Model

5. Provide a brief summary or description of the required payment arrangement selected above and describe how the payment arrangement intends to recognize value or outcomes over volume of services (the State may also provide an attachment). If “other” was checked above, identify the payment model. If this payment arrangement is designed to be a multi-year effort, describe how this application’s payment arrangement fits into the larger multi-year effort. If this is a multi-year effort, identify which year of the effort is addressed in this application.

California will continue the DMPH QIP through PY 6. Effective PY 4, the State will direct Medi-Cal managed care health plans (MCPs) to make QIP payments tied to performance on designated performance measures in categories such as, but not limited to, primary care access and preventive care, acute and chronic care, behavioral health, maternal health, patient safety, and overuse/appropriateness of care. This program will support the State’s quality strategy by promoting access and value-based payment, increasing the amount of funding tied to quality outcomes, while at the same time further aligning state, MCP, and DMPH system goals. This payment arrangement moves California towards value-based alternative payment models. It integrates historical supplemental payments to come into compliance with the managed care rule by linking payments to the utilization and delivery of services under the MCP contracts.

Additionally, QIP PY 4 completes the PRIME to QIP Transition that incorporated the quality improvement and funding from the Public Hospital Redesign and Incentives in Medi-Cal (PRIME) Program that was established as part of the California Medi-Cal 2020 Demonstration (11-W-00193/9). California seeks to maintain and continue the momentum achieved with DMPHs on improvements in the quality of care delivered to Medi-Cal beneficiaries. Otherwise, the continuous quality improvement and delivery system reforms related to the PRIME Program would have terminated on June 30, 2020 with the Medi-Cal 2020 Demonstration.

#### STATE DIRECTED FEE SCHEDULES:

6. In accordance with §438.6(c)(1)(iii), the State is requiring the MCO, PIHP, or PAHP to adopt a minimum or maximum fee schedule for network providers that provide a particular service under the contract; or the State is requiring the MCO, PIHP, or PAHP to provide a uniform dollar or percentage increase for network providers that provide a particular service under the contract. *Check all that apply; if none are checked, proceed to Question 10.*

Not applicable

- Minimum Fee Schedule
- Maximum Fee Schedule
- Uniform Dollar or Percentage Increase

7. Use the checkboxes below to identify whether the State is proposing to use §438.6(c)(1)(iii) to establish any of the following fee schedules:

Not applicable

- The State is proposing to use an approved State plan fee schedule
- The State is proposing to use a Medicare fee schedule
- The State is proposing to use an alternative fee schedule established by the State

8. If the State is proposing to use an alternative fee schedule established by the State, provide a brief summary or description of the required fee schedule and describe how the fee schedule was developed, including why the fee schedule is appropriate for network providers that provide a particular service under the contract (the State may also provide an attachment).

Not applicable

9. If using a maximum fee schedule, use the checkbox below to make the following assurance:

- In accordance with §438.6(c)(1)(iii)(C), the State has determined that the MCO, PIHP, or PAHP has retained the ability to reasonably manage risk and has discretion in accomplishing the goals of the contract.

Not applicable

**APPROVAL CRITERIA FOR ALL PAYMENT ARRANGEMENTS:**

10. In accordance with §438.6(c)(2)(i)(A), describe in detail how the payment arrangement is based on the utilization and delivery of services for enrollees covered under the contract (the State may also provide an attachment).

Payments under the QIP will be made to DMPH systems for meeting designated performance measures that are linked to the utilization and delivery of services under the MCP contracts. Performance standards will be applied equally within a single class. Hospitals will be rewarded for meeting the performance goals, measured for all Medi-Cal beneficiaries utilizing services at, or assigned by MCPs to, the DMPH system. California will specify the maximum allowable payment amount under the QIP, which will be included in the supporting documentation in the rate submission process. See Attachment 1 for further detail.

11. In accordance with §438.6(c)(2)(i)(B), identify the class or classes of providers that will participate in this payment arrangement.

**Class of Providers**

- 1) Public hospitals defined by CA Welfare & Institutions Code section 14105.98(a)(25) excluding Designated Public Hospitals as defined by CA Welfare & Institutions Code section 14184.10(f)(1), hereafter known as District and Municipal Public Hospital (DMPH) systems.

12. In accordance with §438.6(c)(2)(i)(B), describe how the payment arrangement directs expenditures equally, using the same terms of performance, for the class or classes of providers (identified above) providing the service under the contract (the State may also provide an attachment).

All participating DMPH systems will report on a minimum number of required performance measures approved by DHCS from as low as 2 to as high as 20, as specified in Attachment 1. The class of providers is heterogeneous in terms of both facility size and array of services provided. As such, each DMPH will be provided an equal opportunity to determine its specific minimum number of required measures for reporting within a range assigned to tiers determined by DHCS (currently there are two tiers in PY 4). The tier to which any particular hospital is assigned is based on its annual Medi-Cal revenue data and Rural hospital designation as defined by CA Health & Safety Code section 124840. As discussed in Attachment 1, targets and performance calculations for each measure uniformly apply to all participating DMPH systems.

**QUALITY CRITERIA AND FRAMEWORK FOR ALL PAYMENT ARRANGEMENTS:**

13. Use the checkbox below to make the following assurance (and complete the following additional questions):

In accordance with §438.6(c)(2)(i)(C), the State expects this payment arrangement to advance at least one of the goals and objectives in the quality strategy required per §438.340.

a. Hyperlink to State’s quality strategy (consistent with §438.340(d), States must post the final quality strategy online beginning July 1, 2018; if a hyperlink is not available, please attach the State’s quality strategy):

<http://www.dhcs.ca.gov/formsandpubs/Documents/ManagedCareQSR062918.pdf>

b. Date of quality strategy (month, year):

June 2018

c. In the table below, identify the goal(s) and objective(s) (including page number references) this payment arrangement is expected to advance:

<b>Table 13(c): Payment Arrangement Quality Strategy Goals and Objectives</b>		
<b>Goal(s)</b>	<b>Objective(s)</b>	<b>Quality strategy page</b>
Enhance quality, including the patient care experience, in all DHCS programs	Deliver effective, efficient, affordable care	Medi-Cal Managed Care Quality Strategy Report, Page 6

- d. Describe how this payment arrangement is expected to advance the goal(s) and objective(s) identified in Question 13(c). If this is part of a multi-year effort, describe this both in terms of this year's payment arrangement and that of the multi-year payment arrangement.

The QIP will advance the State's Quality Strategy through the use of targeted performance measures to drive DMPH improvement in categories such as, but not limited to, primary care access and preventive care, acute and chronic care, behavioral health, maternal health, patient safety, and overuse/appropriateness of care. In order to receive QIP payments, DMPHs must achieve specified improvement targets. QIP PYs 4-6 are anticipated to continue the substantial year-over-year improvement in QIP and PRIME since their inception and to continue to promote access, value-based payment, and tie funding to quality outcomes, while at the same time further aligning state, MCP, and DMPH system goals. Due to the COVID-19 Public Health Emergency (PHE), DHCS will temporarily modify the PY 4 measures and improvement targets otherwise applicable to QIP PYs 4-6 as outlined in Attachment 1.

The QIP creates a robust data monitoring and reporting mechanism which incentivizes quality data. This information will enable dependable data-driven analysis, issue spotting and solution design. The QIP also creates incentives to build hospital system data and quality infrastructure and ties provider funding directly to these goals, allowing California to pay for quality and build capacity. Finally, implementing QIP will also drive changes to policy and legal frameworks to facilitate future data-driven

14. Use the checkbox below to make the following assurance (and complete the following additional questions):

In accordance with §438.6(c)(2)(i)(D), the State has an evaluation plan which measures the degree to which the payment arrangement advances at least one of the goal(s) and objective(s) in the quality strategy required per §438.340.

- a. Describe how and when the State will review progress on the advancement of the State’s goal(s) and objective(s) in the quality strategy identified in Question 13(c). If this is any year other than year 1 of a multi-year effort, describe prior year(s) evaluation findings and the payment arrangement’s impact on the goal(s) and objective(s) in the State’s quality strategy. If the State has an evaluation plan or design for this payment arrangement, or evaluation findings or reports, please attach.

Please see Attachment 2.

- b. Indicate if the payment arrangement targets all enrollees or a specific subset of enrollees. If the payment arrangement targets a specific population, provide a brief description of the payment arrangement’s target population (for example, demographic information such as age and gender; clinical information such as most prevalent health conditions; enrollment size in each of the managed care plans; attribution to each provider; etc.).

The payment arrangement targets all Medi-Cal managed care enrollees receiving care from, or assigned by MCPs to, participating DMPHs. The QIP is not intended to drive quality improvement for a specific subgroup of Medi-Cal enrollees. Certain subsets of enrollees or populations may be excluded from the QIP arrangement as necessary for actuarial or other reasons.

- c. Describe any planned data or measure stratifications (for example, age, race, or ethnicity) that will be used to evaluate the payment arrangement.

At its discretion, DHCS may require stratification for a subset of measures by age, gender, and/or race/ethnicity. Starting in PY 4, DHCS will implement a Health Equity measure for DMPHs to continue work on disparity reduction, which will require stratification to identify the population targeted for quality improvement.

- d. Provide additional criteria (if any) that will be used to measure the success of the payment arrangement.

Not applicable.



**REQUIRED ASSURANCES FOR ALL PAYMENT ARRANGEMENTS:**

15. Use the checkboxes below to make the following assurances:

In accordance with §438.6(c)(2)(i)(E), the payment arrangement does not condition network provider participation on the network provider entering into or adhering to intergovernmental transfer agreements.

In accordance with §438.6(c)(2)(i)(F), the payment arrangement is not renewed automatically.

In accordance with §438.6(c)(2)(i), the State assures that all expenditures for this payment arrangement under this section are developed in accordance with §438.4, the standards specified in §438.5, and generally accepted actuarial principles and practices.

**Additional Questions for Value-Based Payment Arrangements**

*In accordance with §438.6(c)(2)(ii), if a checkbox has been marked for Question 4, the following questions must also be completed.*

**APPROVAL CRITERIA FOR VALUE-BASED PAYMENT ARRANGEMENTS:**

16. In accordance with §438.6(c)(2)(ii)(A), describe how the payment arrangement makes participation in the value-based purchasing initiative, delivery system reform, or performance improvement initiative available, using the same terms of performance, to the class or classes of providers (identified above) providing services under the contract related to the reform or improvement initiative (the State may also provide an attachment).

See Attachment 1.

**QUALITY CRITERIA AND FRAMEWORK FOR VALUE-BASED PAYMENT ARRANGEMENTS:**

17. Use the checkbox below to make the following assurance (and complete the following additional questions):

In accordance with §438.6(c)(2)(ii)(B), the payment arrangement makes use of a common set of performance measures across all of the payers and providers.

a. In the table below, identify the measure(s) that the State will tie to provider performance under this payment arrangement (provider performance measures). To the extent practicable, CMS encourages States to utilize existing validated performance measures to evaluate the payment arrangement.

<b>TABLE 17(a): Payment Arrangement Provider Performance Measures</b>					
<b>Provider Performance Measure Number</b>	<b>Measure Name and NQF # (if applicable)</b>	<b>Measure Steward/ Developer (if State-developed measure, list State name)</b>	<b>State Baseline (if available)</b>	<b>VBP Reporting Years*</b>	<b>Notes**</b>
1.	<b>See Attachment 1, Part A.</b>				
2.					
3.					
4.					
5.					
6.					
If additional rows are required, please attach.					

\*If this is planned to be a multi-year payment arrangement, indicate which year(s) of the payment arrangement the measure will be collected in.

\*\*If the State will deviate from the measure specification, please describe here. Additionally, if a State-specific measure will be used, please define the numerator and denominator here.

- b. Describe the methodology used by the State to set performance targets for each of the provider performance measures identified in Question 17(a).

**See Attachment 1, B. Target Setting and Performance Measurement.**

**REQUIRED ASSURANCES FOR VALUE-BASED PAYMENT ARRANGEMENTS:**

18. Use the checkboxes below to make the following assurances:

In accordance with §438.6(c)(2)(ii)(C), the payment arrangement does not set the amount or frequency of the expenditures.

In accordance with §438.6(c)(2)(ii)(D), the payment arrangement does not allow the State to recoup any unspent funds allocated for these arrangements from the MCO, PIHP, or PAHP.

## ATTACHMENT 1

### **438.6(c) Proposal – DMPH QIP Directed Payments Performance Standards and Payment Specifications Program Years 4–6: January 1, 2021 – December 31, 2023**

Payments under the QIP will be made to DMPH systems for meeting designated performance measures that are linked to the utilization and delivery of services under the MCP contracts. Performance standards will be applied equally within the class. Hospitals will be rewarded for meeting the performance goals specified below. Achievement of measure targets will be measured as specified in the QIP manual established for each program year (PY). As specified earlier, each PY is a calendar year. The payment arrangement described in this preprint constitutes the total DMPH QIP program payment for PYs 4-6 and supersedes all other payment authorizations for the DMPH QIP program during that period. California will specify the maximum allowable payment amount under the DMPH QIP annually, which will be included in the supporting documentation through the rate submission process.

	PY 4, CY 2021	PYs 5-6
DMPH QIP (Total Computable)	\$155.95 million	$PY(n) = (\$155.95 \text{ million}) \times ((1 + \text{Growth Rate})^{(PY(n)-PY(4))})$

<sup>a</sup>Growth Rate: annual growth rate will be the Consumer Price Index for All Urban Consumers (CPI-U) Hospital and Related Services, Source: Bureau of Labor Statistics

Additionally, for PYs 5 and 6, this preprint establishes the ability to earn additional funds through over-performance, which would allow a DMPH, through all claiming mechanisms, to earn up to 100 percent of its maximum allowable payment amount.

#### A. Performance Measures

For QIP measures, the State will direct MCPs to make performance-based quality incentive payments to DMPHs based on achievement of targets for quality of care. The quality measures will be measured across all Medi-Cal beneficiaries. All such measures will be based on utilization and delivery of services.

The proposed performance measures include process, outcomes, system transformation, and other indicators that are consistent with state, MCP, and DMPH delivery system reform and quality strategy goals. Measures are drawn from nationally vetted and endorsed measure sets (e.g., National Quality Forum, National Committee for Quality Assurance, the Joint Commission, etc.) or measures in wide use across Medicare and Medicaid quality initiatives (e.g., the Medicaid Child and Adult Core Set Measures, CMS Core Quality Measures Collaborative measure sets, Health Home measure sets, Behavioral Health Clinic measure sets, and Merit-based Incentive Payment System and Alternative Payment Model measures, etc.). Performance measures must include known benchmarks applicable to the Medicaid population, and must meet one or more of the following criteria:

- is an NQF-endorsed measure,
- is considered a national Medicaid performance measure, or
- has been used with financial performance accountability in a CMS approved performance program and is not duplicative of a current CMS approved Medicaid program.

These criteria may be waived by DHCS for measures implemented due to the COVID-19 Public Health Emergency (PHE) as detailed below.

Measures selected will not duplicate any measures for which federal funds are already available to DMPH systems, unless approved by DHCS. Prior to the start of the each Program Year, the State may work with the DMPH systems and MCPs to update and revise the measures, measure sets, and target setting methodology as needed to reflect current clinical practices and changes to national measures. Each DPMH system will report on a minimum number of required measures as instructed in the QIP Reporting Manual. The list of performance measures is included below in Tables 1 and 2.

The list of performance measures included in Tables 1 and 2 is subject to change pending availability of benchmarking data, measure changes at the national level, and other factors. Any changes to performance measures will be uniformly treated for all DMPHs within a single class, and is subject to DHCS approval.

For PY 4 only, due to the COVID-19 Public Health Emergency (PHE), each DMPH will report on an additional 5 COVID-19 related measures (included in Table A) and a minimum number of measures from Tables 1 and 2 as follows:

- DMPHs reporting 5 or more measures from Tables 1 and 2 will report 20% of their measures (rounded to the nearest whole number) on a pay-for-performance basis. DMPHs reporting 4 or fewer measures from Tables 1 and 2 do not have to report on a pay-for-performance basis and may instead report on the 2 infrastructure measures as outlined in Table B.
- The remainder of each DMPH’s measures will be pay-for-reporting to set a baseline for CY 2022 (PY 5).

This section supersedes any conflicting sections regarding PY 4 measures only.

Table A: COVID-19 PHE Measures

DMPH systems must report on all COVID-19 measures in PY 4.

<b>QIP COVID-19 PHE Measures</b>
Implementation of employee COVID-19 testing in 2021
Implementation of employee COVID-19 vaccination in 2021
Implementation of infrastructure and partnerships for the provision of COVID-19 tests to Medi-Cal beneficiaries and community members in 2021
Implementation of infrastructure and partnerships for the provision of COVID-19 vaccines to Medi-Cal beneficiaries and community members in 2021
Implementation of hospital surge planning and/or response in 2021

Table B: QIP Infrastructure Measures

<b>QIP Infrastructure Measures</b>
Identification of QIP staffing needs for quality improvement and reporting
Identification of QIP data needs for tracking and reporting

**Table 1: Priority QIP Performance Measures**

DMPHs must select priority measures for at least 50 percent of their minimum required reported measures. In the event that the DMPH cannot achieve a denominator of at least 30 for a required priority measure or does not provide the relevant clinical service needed for the measure, the DMPH will be allowed to substitute a measure from the elective measure list (Table 2). However, the DMPH must demonstrate to DHCS that no other priority measure can be reported with a denominator of at least 30 before substituting an elective measure.

<b>QIP Priority Performance Measures</b>
Improving Health Equity #1**
Asthma Medication Ratio*
Breast Cancer Screening*
Cervical Cancer Screening
Child and Adolescent Well Care Visits
Childhood Immunization Status (CIS 10)
Chlamydia Screening in Women
Colorectal Cancer Screening
Comprehensive Diabetes Care: Eye Exam
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%)*
Controlling High Blood Pressure
Developmental Screening in the First Three Years of Life
HIV Viral Load Suppression
Immunizations for Adolescents
Prenatal and Postpartum Care (Postpartum Care)* <sup>1</sup>
Prenatal and Postpartum Care (Timeliness of Prenatal Care)* <sup>1</sup>
Preventive Care and Screening: Influenza Immunization
Preventive Care and Screening: Screening for Depression and Follow-Up Plan
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Well-Child Visits in the First 30 Months of Life

\* Measures eligible for use of community partner’s data as described in Section C.4

\*\* Improving Health Equity measure allowable for community partner’s data, as described in Section C.4, only if DMPH is engaging on improving equity for a measure that is eligible for use of community partner’s data.

1. Prenatal and Postpartum care measures are a pair of measures. Entities must report both measures if selecting to report on these measures and cannot only report one measure.

**Table 2: Elective QIP Performance Measures**

DMPHs must select measures from the list below to meet the minimum number of measures required for reporting.

<b>Elective QIP Performance Measures</b>
Advance Care Plan
Appropriate Treatment for Upper Respiratory Infection
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis
Cesarean Birth (PC-02)
Comprehensive Diabetes Control: Medical Attention for Nephropathy <sup>1</sup>
Concurrent Use of Opioids and Benzodiazepines*
Contraceptive Care – All Women <sup>1</sup>
Coronary Artery Disease: Antiplatelet Therapy
Coronary Artery Disease: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Depression Remission or Response for Adolescents and Adults
Discharged on Antithrombotic Therapy (STK-2)
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older
Exclusive Breast Milk Feeding (PC-05)
Follow-Up After ED Visit for Alcohol and Other Drug Abuse or Dependence*
Follow-Up After High-Intensity Care for Substance Use Disorder <sup>2</sup>
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Nepriylisin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)*
HIV Screening
Improving Health Equity #2**
Kidney Evaluation for Diabetes <sup>2</sup>
Lead Screening in Children
Medication Reconciliation Post-discharge*
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Pharmacotherapy Management of COPD Exacerbation*
Pharmacotherapy for Opioid Use Disorder <sup>2</sup>
Plan All-Cause Readmissions
Prenatal Immunization Status <sup>2</sup>
Prevention of Central Venous Catheter (CVC) Related Bloodstream Infections
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
Reduction in Hospital Acquired C Difficile Infections
Statin Therapy For The Prevention And Treatment Of Cardiovascular Disease
Surgical Site Infection (SSI)
Use of Imaging Studies for Low Back Pain
Use of Opioids at High Dosage in Persons Without Cancer*
Weight Assessment & Counseling for Nutrition and Physical Activity for Children & Adolescents

\* Measures eligible for use of community partner’s data as described in Section C.4

\*\* Improving Health Equity measure allowable for community partner’s data, as described in Section C.4, only if DMPH is engaging on improving equity for a measure that is eligible for use of community partner’s data.

1. *Effective for PY 4 only*
2. *Effective for PYs 5 and 6 only*

## B. Target Setting and Performance Measurement

For pay-for-performance measures in PY 4, to achieve the performance target, DMPHs must perform at or above the PY 4 minimum performance benchmark established by DHCS as outlined in section C below. This section supersedes any conflicting sections regarding target setting in PY 4 only. All other QIP requirements will continue to apply for target setting and performance measurement for subsequent PYs.

For PYs 5 and 6, targets and performance will be determined as follows:

1. *Target Setting for QIP measures: 10% Gap Closure*

The gap is defined as the difference between the DMPH system's performance for the baseline period (the prior CY) and the high performance benchmark. The target setting methodology will be a 10% gap closure. DMPHs will be required to perform at or above the minimum performance benchmark. DMPHs with baseline performance on a given measure at or above the top performance benchmark for that measure will be required to achieve performance that maintains or exceeds that measure's high performance benchmark. Please see Table 3 below for achievement values based on gap closure targets.

An example of this target setting methodology for PY 5 is as follows:

- Improvement: performance > minimum performance benchmark and < high performance benchmark
  - 10% gap closure between performance for the period of January 1, 2021 – December 31, 2021 (also referred to as baseline) & PY 5 high performance benchmark
    - *Example: Behavioral Health Care Performance Measure X*
      - *PY 5 High Performance Benchmark: 70.0%*
      - *Baseline: 55.0%*
        - » *Gap: 70% - 55% = 15%*
        - » *10% of 15% = 1.5%*
        - » *55% + 1.5% = 56.5% = PY 5 Target*

For select measures that require risk adjustment, DHCS may create an alternate target setting methodology, utilizing information available from federal and state health agencies (including the Centers for Disease Control and Prevention's National Healthcare Safety Network and the National Committee for Quality Assurance), to account for risk adjustment.

2. *Benchmarks*

- a. For measures that have national Medicaid benchmarks, the minimum and high performance benchmarks will be the 25<sup>th</sup> and 90<sup>th</sup> percentiles respectively. For measures with national Medicaid benchmarks, the 50<sup>th</sup> percentile will also be used when assessing over-performance as described below in section B.3.
- b. For measures which have no Medicaid benchmark, DHCS will establish appropriate minimum and high performance benchmarks by using processes and criteria approved for identifying benchmarks for non-Medicaid benchmarked measures in the PRIME program. This process takes into account available performance data on a given measure, be it national, state, or public hospital-specific data, as well as known variances between the populations measured by the available performance data and the managed care Medi-Cal populations measured by QIP. DHCS may update these benchmarks annually, as appropriate based on the most recently available data. DHCS will also establish a median benchmark for assessing high performance on priority measures as described in Section B.3 when necessary.

### 3. Over-Performance

DMPH systems that perform according to the following criteria on measures will be eligible to earn additional funds through over-performance. Through all claiming mechanisms, including over-performance, a DMPH can earn up to 100 percent of its maximum allowable payment amount.

- a. For priority measures to earn over-performance values by Method 1 (as described below):
  - i.  $\geq 15\%$  and  $< 20\%$  gap closure, and  $\geq 50$ th percentile/median benchmark, or
  - ii.  $\geq 20\%$  gap closure and  $\geq 50$ th percentile/median benchmark, or
  - iii.  $\geq 90$ th percentile benchmark
- b. For elective measures to earn over-performance values by Method 2 (as described below):
  - i.  $\geq 15\%$  and  $< 20\%$  gap closure, and  $\geq 50$ th percentile/median benchmark, or
  - ii.  $\geq 20\%$  gap closure and  $\geq 50$ th percentile/median benchmark

### C. Achievement Values

*Pay-for-Performance:* The achievement value of a measure will be based on the amount of progress made toward achieving the measure's performance target.

For PY 4 only, due to the COVID-19 PHE, the AV for pay-for-performance measures in Tables 1 and 2 will be determined as follows:

- PY 4 performance  $<$  minimum performance benchmark, AV = 0
- PY 4 performance  $\geq$  minimum performance benchmark, AV = 1

For PY 4 COVID PHE/ Infrastructure measures in Tables A and B only, the AV will be determined as follows:

- Successful implementation of the measure as determined by DHCS, AV = 1
- Unsuccessful or incomplete implementation of measure as determined by DHCS, AV = 0



For subsequent PYs, achievement will be determined as described below:

1. Based on the progress reported, and using the target setting methodologies described in B.1 above, the achievement value (AV) will be determined as outlined below in Table 3.

**Table 3: Measure Performance Achievement**

	Achievement Values (AV)			
Measure Performance in Prior CY	AV = 0	AV = 0.5	AV = 0.75	AV = 1.0
≥ High Performance Benchmark	Performance < High Performance Benchmark	NA	NA	Performance ≥ High Performance Benchmark
≥ Minimum Performance Benchmark and < High Performance Benchmark	< 50% of the 10% Gap is closed	≥ 50 % to <75% of the 10% Gap is closed	≥ 75 % to <100% of the 10% Gap is closed	100% of the 10% Gap is closed
< Minimum Performance Benchmark Track A: If gap between performance and the Minimum Performance Benchmark ≥ 10% gap between performance and High Performance Benchmark	Performance < Minimum Performance Benchmark	NA	NA	Performance ≥ Minimum Performance Benchmark
< Minimum Performance Benchmark Track B: If gap between performance and Minimum Performance Benchmark is < 10% gap between performance and High Performance Benchmark	Performance < Minimum Performance Benchmark, or performance ≥ Minimum Performance Benchmark and < 50% of the 10% gap is closed	Performance ≥ Minimum Performance Benchmark and ≥ 50 % to <75% of the 10% gap is closed	Performance ≥ Minimum Performance Benchmark and ≥ 75 % to <100% of the 10% gap is closed	100% of the 10% gap is closed

2. DMPH systems choosing to report on a measure for which they have not reported baseline data must report statistically valid (denominator must be at least 30) historical data from the prior CY to establish a baseline in order to receive an AV for that measure. This requirement will not apply to PY 4 due to the COVID-19 PHE.
3. Furthermore, unless otherwise specified by DHCS, each reported measure must include data from at least one person enrolled in Medi-Cal managed care during the reporting PY in order to receive an AV for that measure in that PY. For reported subrated measures, at least one subrate must include data from at least one person enrolled in Medi-Cal managed care. An entity will

earn an AV of zero and will not receive payment for a reported measure in which data does not include at least one Medi-Cal managed care life. However, the measure may still be used to fulfill the required number of measures for an entity’s QIP reporting.

4. For a select group of measures outlined by DHCS in Tables 1 and 2 above, DMPHs may use data from DHCS-approved contracted community partners’ patients in their QIP reports. Only specific QIP measures where the DMPH has a demonstrated role in the coordination of care and achievement of the measure will be considered for this allowance. These measures generally include patients who have had an emergency room or inpatient encounter at the DMPH and measure quality activities that could reasonably be undertaken by the DMPH. All DMPHs with DHCS community partner approval must include all data from the community partner’s patients that meet measure denominator criteria and have had at least one encounter with the DMPH during the measurement period.

Note, for the following measure, the qualifying DMPH encounter(s) cannot be the same as the numerator-qualifying encounter(s):

- Breast Cancer Screening – mammogram encounter cannot be the only DMPH encounter

Further, the Improving Health Equity measure is allowable for community partner data for up to two measures, as described in Tables 1 and 2 above.

#### D. Over-performance Values

The over-performance claiming mechanism will not be available for PY 4. This section supersedes any conflicting sections regarding PY4 over-performance.

##### *1. Determining Over-performance Values*

The over-performance value of a measure will be based on the amount of progress made toward the measure’s performance target. Based on the progress reported, and using the target setting methodologies for over-performance described in B.3, the over-performance value (OV) will be determined as outlined in Table 4 below.

**Table 4: Over-Performance Values**

<b>Progress toward performance target</b>	<b>Over-performance Values (OV) for Over-performance on Priority Measures (Method 1)</b>	<b>Over-performance Values (OV) for Over-performance on Elective Measures (Method 2)</b>
≥ 15% and < 20% gap closure, and ≥50th percentile/median benchmark	0.5	0.25
≥ 20 gap closure and ≥50th percentile/median benchmark	1.0	0.50
≥90 <sup>th</sup> percentile	1.0	N/A

## 2. *Using Over-performance Values*

- a. Over-performance values earned through over-performance on priority measures via Method 1 may be used to earn remaining priority measure achievement values and/or remaining elective measure achievement values. “Remaining achievement value” equals the number of reported measures minus total achievement values.
- b. Over-performance values earned through over-performance on elective measures via Method 2 may be used to earn remaining priority measure achievement values and/or remaining elective measures achievement values with the following limitations:
  - i. In PYs 5 and 6, over-performance values earned through over-performance on elective measures may be used to earn:
    - ≤ 2 remaining priority measure achievement values, and
    - Any remaining elective measure achievement values.

### E. Over-performance Incentive Process

Each DMPH system may earn additional funds through over-performance, as described in B.3 and D, and in accordance with the following process. A DMPH can earn up to 100 percent of its maximum allowable payment amount through all claiming mechanisms, including over-performance.

1. Calculate the DMPH system’s reported total achievement values and total remaining measure achievement values separately for priority measures and elective measures.
2. Calculate the DMPH system’s reported total over-performance values separately for priority measures and elective measures.
3. First, apply over-performance values earned through over-performance on priority measures by Method 1 to earn the DMPH system’s remaining priority measure achievement values first, as available, and then to earn the DMPH system’s remaining elective measure achievement values, until the DMPH system exhausts its remaining over-performance values earned through over-performance on priority measures, or until the DMPH system has earned all of its remaining achievement values.
4. Second, apply over-performance values earned through over-performance on elective measures via Method 2 to earn the DMPH system’s remaining priority measure achievement values and/or remaining elective measure achievement values, under the limitations described in D.2.b, until the DMPH system uses all of its over-performance values earned through over-performance on elective measures, or until the DMPH system has earned all of its remaining achievement values.

Over-performance Example for PY 5:

- DMPH system A reports full achievement on 16 priority measures and 19 elective measures.
  - DMPH system A achieves less than 5 percent gap closure, thus completely misses targets on 4 priority measures and 1 elective measure.
  - Its remaining priority measure achievement value is 4 and its remaining elective measure achievement value is 1.

- DMPH system A over-performs on 1 priority measure, worth 1 over-performance value and over-performs on 5 elective measures, worth 2.5 over-performance values.
- First, DMPH A applies its 1 over-performance value from over-performance on priority measures via Method 1 to earn 1 of the 4 remaining priority measure achievement values.
  - DMPH system A has now used all of its over-performance values earned through over-performance on priority measures.
  - DMPH system A still has 3 remaining priority measure achievement values and 1 remaining elective measure achievement value.
- Second, DMPH system A has 2.5 over-performance values from over-performance on elective measures via Method 2.
  - In PY 5, DMPH system A can only use 2 of these over-performance values to earn 2 of the 3 remaining priority measure achievement values, and can use the balance of its 0.5 over-performance value to earn 0.5 of the 1 remaining elective measure achievement value.
- After accounting for over-performance values, the DMPH has earned a total of 3.5 remaining measure achievement values, and has a total of 1.5 remaining elective measure achievement values that it cannot make-up via over-performance.

*Final QIP Payments:*

For PY4 only, due to the COVID-19 PHE, each DMPH's maximum allowable payment amount will be paid according to the following distribution:

- 50% of payment: based on achievement of 5 COVID-19 related measures.
- 20% of payment: based on pay-for-performance for 20% of their measures (DMPHs reporting 5 or more measures) or 2 infrastructure measures as outlined in Table B (DMPHs with a minimum number of 4 or fewer required measures).
- 30% of payment: based on reporting their remaining measures. Reporting the measures, as specified by DHCS, will be considered full achievement for meeting these measures' PY 4 targets.

The maximum allowable payment amount that may be earned by a specific DMPH from the QIP pool (i.e., the amount earned if the DMPH attains all of its selected quality targets) will be derived from their Medi-Cal revenue and the amount of selected measures relative to all other participating DMPHs. Payments will be made based on a Quality Score that measures the sum of the achievement values for all measures selected for reporting by the DMPH system divided by the number of measures it selected for reporting. Each DMPH's maximum allowable payment amount will be multiplied by the DMPH's Quality Score to determine the DMPH's QIP base payment.

Additionally, as described in Sections B.3, D and E, for PYs 5 and 6, each DMPH system may earn additional funds through over-performance, up to a total of 100 percent of its maximum allowable payment amount through all claiming mechanisms.

Example: DMPH system B has a maximum allowable payment amount of \$400 and reports 40 measures.

- The full funding value of each measure for DMPH system B = \$10

- DMPH system B meets targets for 19 priority measures and 18 elective measures; DMPH system B earns **\$370** as a base payment.
  - DMPH system B has 1 remaining priority measure achievement value (missed 1 of 20 priority measures) and 2 remaining elective measure achievement values (missed 2 of 20 elective measures) that are eligible to be earned through over-performance.
- DMPH system B over-performs at 20% gap closure on 1 priority measure, earning an over-performance value of 1. It applies that over-performance value of 1 to the 1 remaining priority measure achievement value and earns 1 measure value, **\$10**.
- DMPH system B also over-performs at 20% gap closure on 1 elective measure, earning an over-performance value of 0.5. It applies that over-performance value of 0.5 to the 2 remaining elective measure achievement values and earns  $0.5 \times \$10$ , or **\$5**. DMPH system B is unable to earn 1.5 remaining elective measure achievement values.
- The sum of DMPH system B payments = \$385

For PYs 5 and 6, each DMPH's base payment and over-performance payment amounts will be added together to determine the DMPH's final QIP payment. The DMPH's final QIP payment must not be greater than 100 percent of the DMPH's maximum allowable payment amount.

The State will require MCPs, via its contracts, All Plan Letters, or similar instruction to make final QIP payments to contracted DMPH systems. The State will identify the amount of final QIP payments each MCP must make to each contracted DMPH system, with the sum of these amounts not to exceed the amount of total funds available in the applicable QIP PY.

If there is more than one MCP in the specific DMPH system's service area, the final QIP payment to the DMPH system will be allocated proportionally among the MCPs by DHCS.

## ATTACHMENT 2

### **CA 438.6(c) Proposal – DMPH QIP Directed Payments Program Years 4–6 Evaluation Plan January 1, 2021 – December 31, 2023**

#### **Evaluation Purpose**

The purpose of this evaluation is to determine if the proposed directed payments made, through California Department of Health Care Services (DHCS) contracts with Medi-Cal Managed Care Plans (MCP) to network provider District and Municipal Public Hospitals (DMPHs), improve the quality of inpatient and outpatient services for Medi-Cal members assigned to DMPHs.

#### **Stakeholders**

- DMPHs
- District Hospital Leadership Forum (DHLF)
- California Association of Health Plans (CAHP)
- Local Health Plans of California (LHPC)
- MCPs

#### **Evaluation Questions**

This evaluation is designed to answer the following question:

Do performance-based quality incentive payments to DMPHs improve the quality of inpatient and outpatient services for Medi-Cal members?

#### **Evaluation Design**

During PYs 4-6, all participating hospital systems will report on a minimum of 2 measures or a maximum of 20 required measures. These measures will be DHCS specified performance measures. Targets and performance calculations for each measure, as discussed in Attachment 1, uniformly apply to all participating hospital systems.

The detailed list of measures is included in Attachment 1.

DHCS will use aggregated data, submitted by DMPHs to DHCS, to determine:

- For each measure, of DMPHs reporting on that measure, what percentage met their quality performance targets.
- For each measure, the aggregate improvement seen across all DMPHs who reported on the measure (this will not apply for the PY 4 evaluation).
- For each DMPH, the percentage of measures for which they meet their quality performance targets.

## Data Collection Methods

DHCS will collect all data necessary for quality measurement from DMPH systems that will be required to report aggregated data on each measure. Depending on the specific measure and DMPH system capabilities, DMPH systems will collect aggregated data utilizing Electronic Health Records and/or claims and registry databases. Using the QIP reporting application, DMPH systems will submit to DHCS encrypted system level performance data collected in the form and manner specified by DHCS. DHCS will conduct its analysis on 100 percent of the data received.

## Timeline

Example for PY 4, with similar timeline for subsequent PYs:

- Program Year 4: January 1, 2021 – December 31, 2021
- June 15, 2022: Deadline for DMPHs to submit QIP data to DHCS
- June 16, 2022 through October 31, 2022: DHCS review of DMPH QIP reports
- November 2022: Data finalized and approved
- November 2022 through February 2023: DHCS will develop the evaluation report
- March 2023: Draft evaluation report reviewed by stakeholders
- April through May 2023: Stakeholder comments incorporated into evaluation report, draft to go through internal review and finalized by program
- May 2023: Evaluation report posted on public DHCS website and sent to CMS

## Communication and Reporting

The results will be shared with the stakeholders listed above and a report will be shared with CMS. The report will also be posted on the State's [QIP website](#).